Articles From: Ocera Therapeutics to Announce Third Quarter 2014 Financial Results to Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2015


PALO ALTO, Calif., Nov.
Sign-up for Ocera Therapeutics to Announce Third Quarter 2014 Financial Results investment picks
PALO ALTO, Calif., Nov.
Sign-up for Ocera Therapeutics to Present at Stifel 2014 Healthcare Conference investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G026287-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/11/13/11G026287/Och-Ziff_LOGO_CMYKgreen2011-1288844306723.jpg NEW YORK, NY--(Marketwired - November 13, 2014) - Och-Ziff Capital Management Group LLC (NYSE: OZM) ("Och-Ziff" or the "Company") today announced that its indirect subsidiary, Och-Ziff Finance Co.
Sign-up for Och-Ziff Capital Management Group LLC Announces Offering of Senior Notes investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G027600-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/12/2/11G027600/Och-Ziff_LOGO_CMYKgreen2011-1288844306723.jpg NEW YORK, NY--(Marketwired - December 02, 2014) - Och-Ziff Capital Management Group LLC (NYSE: OZM) (the "Company" or "Och-Ziff ") announced today that Daniel S.
Sign-up for Och-Ziff Capital Management Group LLC to Present at the Goldman Sachs U.S. Financial Services Conference investment picks
2014/11/5
NEDERLAND, Texas , Nov.
Sign-up for OCI Partners LP Schedules 2014 Third Quarter Results Conference Call investment picks
OCI Resources LP (the "Partnership") (NYSE: OCIR) announced today the approval, on January 15, 2015, of an increase to its quarterly distribution by the board of directors of its general partner.
Sign-up for OCI Resources LP Increases Quarterly Cash Distribution investment picks
OCI Resources LP (NYSE: OCIR) announced today that it will release third quarter 2014 financial results after the market closes Tuesday, November 4, 2014.
Sign-up for OCI Resources LP To Release Third Quarter 2014 Financial Results investment picks
SAN JOSE, Calif.
Sign-up for Oclaro Announces First Quarter Fiscal Year 2015 Financial Results investment picks
SAN JOSE, Calif.
Sign-up for Oclaro to Present at the Needham Annual Growth Conference investment picks
2015/1/7
OCP Credit Funds confirms quarterly distributions Canada NewsWire /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES / TORONTO , Jan.
Sign-up for OCP Credit Funds confirms quarterly distributions investment picks
2014/11/3
LONDON , November 3, 2014 /PRNewswire/ -- Chrysler Automobiles announces that Chrysler Group LLC released today, through PR Newswire, US retail sales in October 2014 .
Sign-up for October 2014 Chrysler Group LLC Sales in USA investment picks
2014/11/18
LONDON , November 18, 2014 /PRNewswire/ -- In Europe (EU28+EFTA), Fiat Chrysler Automobiles posted October sales up 8.4% year-over-year versus 6.2% for the industry overall.
Sign-up for October 2014 Fiat Chrysler Automobiles Sales in Europe investment picks
Cars.com reports SUV and truck sales propel new-car market to YTD highs CHICAGO , Nov.
Sign-up for October Average Transaction Price Reaches Highest Mark of 2014 investment picks
2014/11/12
NEW YORK , Nov.
Sign-up for October Sees Further Consolidation in Commodity Markets investment picks
By Tess Stynes American Airlines Group Inc. and Southwest Airlines Co.
Sign-up for October traffic edges up at American, Southwest investment picks
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced top line results for a Phase 2 clinical trial evaluating Sustained Release Dexamethasone (OTX-DP) for treatment of allergic conjunctivitis.
Sign-up for Ocular Therapeutix™ Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis investment picks
Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today enrollment of the first patient in a Phase 2 clinical trial to evaluate the safety and efficacy of Sustained Release Dexamethasone (OTX-DP), an ophthalmic corticosteroid for the treatment of inflammatory dry eye disease.
Sign-up for Ocular Therapeutix™ Enrolls First Patient in Phase 2 Clinical Trial for Sustained Release Dexamethasone for the Treatment of Dry Eye Disease investment picks
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today enrollment of the first patients in a Phase 2b clinical trial evaluating Sustained Release Travoprost (OTX-TP) for the reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension.
Sign-up for Ocular Therapeutix™ Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release Travoprost for the Treatment of Glaucoma and Ocular Hypertension investment picks
Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter ended September 30, 2014, and provided an update on current business developments.
Sign-up for Ocular Therapeutix™ Reports Third Quarter 2014 Financial Results investment picks
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will be presenting at two upcoming investor conferences: About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.
Sign-up for Ocular Therapeutix™ to Participate in Two Investor Conferences in November 2014 investment picks
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 25th Annual Healthcare Conference on Thursday, December 11, 2014 at 3:20 p.m. Eastern Time at the Crowne Plaza Hotel in New York City.
Sign-up for Ocular Therapeutix™ to Present at Oppenheimer 25th Annual Healthcare Conference investment picks
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter 2014 financial results on Wednesday, November 12, 2014 at 7:00 a.m. Eastern Time.
Sign-up for Ocular Therapeutix™ to Report Third Quarter 2014 Financial Results and Provide Business Updates on Wednesday, November 12, 2014 investment picks
Multiple Microcyn®-Based Dermatology Products for Management of Pain/Itch and Scar Management Now Commercialized in the United States Four New Dermatology Products for Management of Scars, Atopic Dermatitis and Mild-to-Moderate Acne Now Commercialized in Europe PETALUMA, Calif., Jan.
Sign-up for Oculus Innovative Sciences Announces New Dermatology Division, IntraDerm Pharmaceuticals investment picks
New GramaDerm™ Solution and Hydrogel to be introduced at Medica Trade Fair on November 12-15 in Dusseldorf, Germany Oculus now offering four clinically proven dermatology products with acne spray, acne gel, scar management and atopic dermatitis to European dermatologists ROERMOND, Netherlands and PETALUMA, Calif., Nov.
Sign-up for Oculus Innovative Sciences Commercializes Microcyn(R)-Based Solution and Hydrogel for Treatment of Mild-to-Moderate Acne in Europe investment picks
• New Pediacyn™ Hydrogel to be Introduced at Medica Education Conference on November 12-15 in Dusseldorf, Germany ROERMOND, Netherlands and PETALUMA, Calif., Oct.
Sign-up for Oculus Innovative Sciences Receives European CE Mark for New Microcyn(R)-Based Atopic Dermatitis Hydrogel investment picks
New Epicyn™ Hydrogel to be Introduced at Medica Trade Fair on November 12-15 in Dusseldorf, Germany ROERMOND, Netherlands and PETALUMA, Calif., Nov.
Sign-up for Oculus Innovative Sciences Receives European CE Mark for New Microcyn(R)-Based Scar Management Hydrogel investment picks
Total revenue of $3.3 million for the second quarter Net loss of $718,000, reduced from $1.4 million in same period last year Oculus owns two million shares of Ruthigen (Nasdaq:RTGN) Net worth of $13.4 million, up $11.9 million from September 30, 2013 Conference Call Begins at 4:30 p.m. (ET) Today PETALUMA, Calif., Nov.
Sign-up for Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2015 investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Ocera Therapeutics to Announce Third Quarter 2014 Financial Results to Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2015
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent